Search Results - "Rücker, Frank"

New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise by Bohl, Stephan R, Bullinger, Lars, Rücker, Frank G

“…The therapeutic approach for acute myeloid leukemia (AML) remains challenging, since over the last four decades a stagnation in standard cytotoxic treatment…”
Get full text

Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations by Rausch, Tobias, Jones, David T.W., Zapatka, Marc, Stütz, Adrian M., Zichner, Thomas, Weischenfeldt, Joachim, Jäger, Natalie, Remke, Marc, Shih, David, Northcott, Paul A., Pfaff, Elke, Tica, Jelena, Wang, Qi, Massimi, Luca, Witt, Hendrik, Bender, Sebastian, Pleier, Sabrina, Cin, Huriye, Hawkins, Cynthia, Beck, Christian, von Deimling, Andreas, Hans, Volkmar, Brors, Benedikt, Eils, Roland, Scheurlen, Wolfram, Blake, Jonathon, Benes, Vladimir, Kulozik, Andreas E., Witt, Olaf, Martin, Dianna, Zhang, Cindy, Porat, Rinnat, Merino, Diana M., Wasserman, Jonathan, Jabado, Nada, Fontebasso, Adam, Bullinger, Lars, Rücker, Frank G., Döhner, Konstanze, Döhner, Hartmut, Koster, Jan, Molenaar, Jan J., Versteeg, Rogier, Kool, Marcel, Tabori, Uri, Malkin, David, Korshunov, Andrey, Taylor, Michael D., Lichter, Peter, Pfister, Stefan M., Korbel, Jan O.

“…Genomic rearrangements are thought to occur progressively during tumor development. Recent findings, however, suggest an alternative mechanism, involving…”
Get full text

Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia by Uckelmann, Hannah J, Kim, Stephanie M, Wong, Eric M, Hatton, Charles, Giovinazzo, Hugh, Gadrey, Jayant Y, Krivtsov, Andrei V, Rücker, Frank G, Döhner, Konstanze, McGeehan, Gerard M, Levine, Ross L, Bullinger, Lars, Vassiliou, George S, Armstrong, Scott A

“…The initiating mutations that contribute to cancer development are sometimes present in premalignant cells. Whether therapies targeting these mutations can…”
Get full text

A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies by Boettcher, Steffen, Miller, Peter G, Sharma, Rohan, McConkey, Marie, Leventhal, Matthew, Krivtsov, Andrei V, Giacomelli, Andrew O, Wong, Waihay, Kim, Jesi, Chao, Sherry, Kurppa, Kari J, Yang, Xiaoping, Milenkowic, Kirsten, Piccioni, Federica, Root, David E, Rücker, Frank G, Flamand, Yael, Neuberg, Donna, Lindsley, R Coleman, Jänne, Pasi A, Hahn, William C, Jacks, Tyler, Döhner, Hartmut, Armstrong, Scott A, Ebert, Benjamin L

“…, which encodes the tumor suppressor p53, is the most frequently mutated gene in human cancer. The selective pressures shaping its mutational spectrum,…”
Get full text

Clinical implications of subclonal TP53 mutations in acute myeloid leukemia by Prochazka, Katharina T, Pregartner, Gudrun, Rücker, Frank G, Heitzer, Ellen, Pabst, Gabriel, Wölfler, Albert, Zebisch, Armin, Berghold, Andrea, Döhner, Konstanze, Sill, Heinz

“…The role of subclonal mutations, defined by a variant allele frequency of <20%, has not been addressed in acute myeloid leukemia yet. We, therefore, analyzed…”
Get full text

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations by Döhner, Konstanze, Schlenk, Richard F., Habdank, Marianne, Scholl, Claudia, Rücker, Frank G., Corbacioglu, Andrea, Bullinger, Lars, Fröhling, Stefan, Döhner, Hartmut

“…To assess the prognostic relevance of mutations in the NPM1 gene encoding a nucleocytoplasmic shuttle protein in younger adults with acute myeloid leukemia…”
Get full text

TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome by Rücker, Frank G., Schlenk, Richard F., Bullinger, Lars, Kayser, Sabine, Teleanu, Veronica, Kett, Helena, Habdank, Marianne, Kugler, Carla-Maria, Holzmann, Karlheinz, Gaidzik, Verena I., Paschka, Peter, Held, Gerhard, von Lilienfeld-Toal, Marie, Lübbert, Michael, Fröhling, Stefan, Zenz, Thorsten, Krauter, Jürgen, Schlegelberger, Brigitte, Ganser, Arnold, Lichter, Peter, Döhner, Konstanze, Döhner, Hartmut

“…To assess the frequency of TP53 alterations and their correlation with other genetic changes and outcome in acute myeloid leukemia with complex karyotype…”
Get full text

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin by Schmalbrock, Laura K., Dolnik, Anna, Cocciardi, Sibylle, Sträng, Eric, Theis, Frauke, Jahn, Nikolaus, Panina, Ekaterina, Blätte, Tamara J., Herzig, Julia, Skambraks, Sabrina, Rücker, Frank G., Gaidzik, Verena I., Paschka, Peter, Fiedler, Walter, Salih, Helmut R., Wulf, Gerald, Schroeder, Thomas, Lübbert, Michael, Schlenk, Richard F., Thol, Felicitas, Heuser, Michael, Larson, Richard A., Ganser, Arnold, Stunnenberg, Hendrik G., Minucci, Saverio, Stone, Richard M., Bloomfield, Clara D., Döhner, Hartmut, Döhner, Konstanze, Bullinger, Lars

“…In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients less than 60 Years old) trial, the multikinase inhibitor midostaurin…”
Get full text

Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia by Krönke, Jan, Bullinger, Lars, Teleanu, Veronica, Tschürtz, Florian, Gaidzik, Verena I., Kühn, Michael W.M., Rücker, Frank G., Holzmann, Karlheinz, Paschka, Peter, Kapp-Schwörer, Silke, Späth, Daniela, Kindler, Thomas, Schittenhelm, Marcus, Krauter, Jürgen, Ganser, Arnold, Göhring, Gudrun, Schlegelberger, Brigitte, Schlenk, Richard F., Döhner, Hartmut, Döhner, Konstanze

“…Mutations in the nucleophosmin 1 (NPM1) gene are considered a founder event in the pathogenesis of acute myeloid leukemia (AML). To address the role of clonal…”
Get full text

Chromothripsis is linked to TP53 alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype by Rücker, Frank G, Dolnik, Anna, Blätte, Tamara J, Teleanu, Veronica, Ernst, Aurélie, Thol, Felicitas, Heuser, Michael, Ganser, Arnold, Döhner, Hartmut, Döhner, Konstanze, Bullinger, Lars

Get full text

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial by Kapp-Schwoerer, Silke, Weber, Daniela, Corbacioglu, Andrea, Gaidzik, Verena I., Paschka, Peter, Krönke, Jan, Theis, Frauke, Rücker, Frank G., Teleanu, Maria-Veronica, Panina, Ekaterina, Jahn, Nikolaus, Herzig, Julia, Kubanek, Lena, Schrade, Anika, Göhring, Gudrun, Fiedler, Walter, Kindler, Thomas, Schroeder, Thomas, Mayer, Karin T., Lübbert, Michael, Wattad, Mohammed, Götze, Katharina S., Horst, Heinz A., Koller, Elisabeth, Wulf, Gerald, Schleicher, Jan, Bentz, Martin, Krauter, Jürgen, Bullinger, Lars, Krzykalla, Julia, Benner, Axel, Schlenk, Richard F., Thol, Felicitas, Heuser, Michael, Ganser, Arnold, Döhner, Hartmut, Döhner, Konstanze

“…Monitoring of measurable residual disease (MRD) provides prognostic information in patients with Nucleophosmin1-mutated (NPM1mut) acute myeloid leukemia (AML)…”
Get full text

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group by Rücker, Frank G., Agrawal, Mridul, Corbacioglu, Andrea, Weber, Daniela, Kapp-Schwoerer, Silke, Gaidzik, Verena I., Jahn, Nikolaus, Schroeder, Thomas, Wattad, Mohammed, Lübbert, Michael, Koller, Elisabeth, Kindler, Thomas, Götze, Katharina, Ringhoffer, Mark, Westermann, Jörg, Fiedler, Walter, Horst, Heinz A., Greil, Richard, Schroers, Roland, Mayer, Karin, Heinicke, Thomas, Krauter, Jürgen, Schlenk, Richard F., Thol, Felicitas, Heuser, Michael, Ganser, Arnold, Bullinger, Lars, Paschka, Peter, Döhner, Hartmut, Döhner, Konstanze

“…We performed serial measurable residual disease (MRD) monitoring in bone marrow (BM) and peripheral blood (PB) samples of 155 intensively treated patients…”
Get full text

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia by Dutta, Sayantanee, Pregartner, Gudrun, Rücker, Frank G, Heitzer, Ellen, Zebisch, Armin, Bullinger, Lars, Berghold, Andrea, Döhner, Konstanze, Sill, Heinz

“…Mutations of the gene occur in a subset of patients with acute myeloid leukemia (AML) and confer an exceedingly adverse prognosis. However, whether different…”
Get full text

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation by Cocciardi, Sibylle, Dolnik, Anna, Kapp-Schwoerer, Silke, Rücker, Frank G., Lux, Susanne, Blätte, Tamara J., Skambraks, Sabrina, Krönke, Jan, Heidel, Florian H., Schnöder, Tina M., Corbacioglu, Andrea, Gaidzik, Verena I., Paschka, Peter, Teleanu, Veronica, Göhring, Gudrun, Thol, Felicitas, Heuser, Michael, Ganser, Arnold, Weber, Daniela, Sträng, Eric, Kestler, Hans A., Döhner, Hartmut, Bullinger, Lars, Döhner, Konstanze

“…Mutations in the nucleophosmin 1 ( NPM1 ) gene are considered founder mutations in the pathogenesis of acute myeloid leukemia (AML). To characterize the…”
Get full text

Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia by Lal, Ridhima, Lind, Karin, Heitzer, Ellen, Ulz, Peter, Aubell, Kristina, Kashofer, Karl, Middeke, Jan M., Thiede, Christian, Schulz, Eduard, Rosenberger, Angelika, Hofer, Sybille, Feilhauer, Birgit, Rinner, Beate, Svendova, Vendula, Schimek, Michael G., Rücker, Frank G., Hoefler, Gerald, Döhner, Konstanze, Zebisch, Armin, Wölfler, Albert, Sill, Heinz

Get full text

The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements by Grasedieck, Sarah, Cabantog, Ariene, MacPhee, Liam, Im, Junbum, Ruess, Christoph, Demir, Burcu, Sperb, Nadine, Rücker, Frank G., Döhner, Konstanze, Herold, Tobias, Pollack, Jonathan R., Bullinger, Lars, Rouhi, Arefeh, Kuchenbauer, Florian

“…Aberrant expression of Ecotropic Viral Integration Site 1 (EVI1) is a hallmark of acute myeloid leukemia (AML) with inv(3) or t(3;3), which is a disease…”
Get full text

Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing by Dolnik, Anna, Engelmann, Julia C., Scharfenberger-Schmeer, Maren, Mauch, Julian, Kelkenberg-Schade, Sabine, Haldemann, Berit, Fries, Tamara, Krönke, Jan, Kühn, Michael W.M., Paschka, Peter, Kayser, Sabine, Wolf, Stephan, Gaidzik, Verena I., Schlenk, Richard F., Rücker, Frank G., Döhner, Hartmut, Lottaz, Claudio, Döhner, Konstanze, Bullinger, Lars

“…Acute myeloid leukemia (AML) is characterized by molecular heterogeneity. As commonly altered genomic regions point to candidate genes involved in…”
Get full text

Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication by Jahn, Nikolaus, Terzer, Tobias, Sträng, Eric, Dolnik, Anna, Cocciardi, Sibylle, Panina, Ekaterina, Corbacioglu, Andrea, Herzig, Julia, Weber, Daniela, Schrade, Anika, Götze, Katharina, Schröder, Thomas, Lübbert, Michael, Wellnitz, Dominique, Koller, Elisabeth, Schlenk, Richard F., Gaidzik, Verena I., Paschka, Peter, Rücker, Frank G., Heuser, Michael, Thol, Felicitas, Ganser, Arnold, Benner, Axel, Döhner, Hartmut, Bullinger, Lars, Döhner, Konstanze

“…Core-binding factor (CBF) acute myeloid leukemia (AML) encompasses AML with inv(16)(p13.1q22) and AML with t(8;21)(q22;q22.1). Despite sharing a common…”
Get full text

SEURAT: visual analytics for the integrated analysis of microarray data by Gribov, Alexander, Sill, Martin, Lück, Sonja, Rücker, Frank, Döhner, Konstanze, Bullinger, Lars, Benner, Axel, Unwin, Antony

“…In translational cancer research, gene expression data is collected together with clinical data and genomic data arising from other chip based high throughput…”
Get full text

Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks by Rücker, Frank G., Lang, Katharina M., Fütterer, Markus, Komarica, Vladimir, Schmid, Mathias, Döhner, Hartmut, Schlenk, Richard F., Döhner, Konstanze, Knudsen, Steen, Bullinger, Lars

“…Histone deacetylase inhibitors (HDACIs) like valproic acid (VPA) display activity in leukemia models and induce tumor-selective cytotoxicity against acute…”
Get full text